Pharma Firmen

Swiss pharmaceutical prices to fall further


Your contacts

The most recent measures implemented for the pharmaceutical sector by the Swiss Federal Council and the Federal Department of Home Affairs effective from 1 May 2012 mean further losses for the pharmaceutical companies in Switzerland. Given global advances in sales and the growth rates for the life sciences sector, at first glance this hardly seems significant, but if we look at the importance of local pharmaceutical, biotech and medtech companies for the Swiss economy, these latest efforts to relieve the burden on the mandatory social health insurance scheme should be seen in a critical light.

Additionally to the comparison of its price in other countries the price-setting process of a pharmaceutical, when initially admitted on the reimbursement list (SL)[1], will continue to include a comparison with state-of-the-art pharmaceutical treatment. This Swiss specific therapeutic value assessment will not be carried out anymore in the subsequent three-yearly re-assessments (see new Art. 65d par. 1bis Health Insurance Ordinance).

With this decision, Switzerland is delegating the structuring of its pharmaceutical prices even more strongly to foreign countries than today. This increasing “implantation” of decisions from other jurisdictions is weakening Switzerland’s autonomy, specifically in an area that falls outside the sphere of current discussions on the (autonomous) implementation of European provisions, as in this instance Switzerland is not adopting EU law but is following decisions by individual states.

The future practice of the Federal Office of Public Health (BAG) will show whether prices will still be determined with great care and autonomy, when drugs are first admitted to the reimbursment list, or whether even at this stage, the procedure will be restricted to “copying” prices that already apply in other countries.

The latter would mean that Switzerland factually will not have a legal or economic vote on the market prices of one of its most important export products, not only during their life cycle, but already upon their introduction to the market.

If not even Switzerland succeeds to determine pharmaceutical prices according to an intellectually sound “equation” that rigorously aims to reflect the complexity of this issue, the life sciences industry runs the risk of finding ever less recognition and financial support for its growing R&D investments, both nationally and internationally.

The new policy will only have a small impact on individual pharmaceutical companies what their scope for action is concerned: In most cases it will be impossible to justify a higher price for a pharmaceutical than in the reference countries at the three-yearly review. There are cases, however, where a higher Swiss price could or even ought to (e.g.) stimulate research, introduce market fairness or boost a specifically effective therapeutic use. Every once in a while it may therefore be necessary to check whether narrow interpretation and general application of this new Art. 65d par. 1bis of the Health Insurance Ordinance might not be inappropriate or designed to promote unequal treatment of two competitors.

It is of utmost importance to individual companies whether an appeal against a three-yearly price alteration decree will have suspensive effect. The complexity of an individual case might justify it, although (older) decisions by the Supreme Court in similar matters suggest otherwise.


[1] As a collection of individual decisions, the Federal Office of Public Health’s list of pharmaceutical specialties determines which drugs must be reimbursed at what price and under what conditions to insured persons with basic health insurance cover, i.e. all Swiss residents.


Share post




Highlights

MLL Legal

MLL Legal is one of the leading law firms in Switzerland with offices in Zurich, Geneva, Zug, Lausanne, London and Madrid. We advise our clients in all areas of business law and stand out in particular for our first-class industry expertise in technical-innovative specialist areas, but also in regulated industries.

MLL Meyerlustenberger Lachenal Froriep

Newsletter

Much is still unclear in relation to liability questions around AI tools.

Read our latest post about “Liability during the Lifecycle of an AI Tool” and download our white paper.

Show article.

Our Story

MLL Legal is a leading Swiss law firm with a history that dates back to 1885. The firm has grown both organically and by means of strategic mergers, the latest of which took place on 1st July 2021 between Meyerlustenberger Lachenal and FRORIEP.

The merger establishes MLL Legal, a combined new entity as one of the largest commercial law firms in Switzerland with 150 lawyers in four offices in Switzerland and two offices abroad, in London and Madrid serving clients seeking Swiss law advice.

Our firm has a strong international profile and brings together recognised leadership and expertise in all areas of law affecting commerce today, with a focus on high-tech, innovative and regulated sectors. 

About us

Publications

Click here for our latest publications

COVID-19

Read all our legal updates on the impact of COVID-19 for businesses.

COVID-19 Information

Job openings

Looking for a new challenge?

Our talented and ambitious teams are motivated by a common vision to succeed. We value open and straightforward communication accross all levels of the organisation in a supportive working environment.

Job openings

Firm News

Click here for our latest firm news.

Our Team

The regulatory and technological landscape continually require businesses to adapt and evolve.
Our 150+ lawyers are continuously innovating and striving for improvement in everything they do. We embrace new ideas and technologies, combining our wealth of expertise with creative thinking and diligence. With our hands-on approach, we implement viable solutions for the most complex legal challenges.

Our Team.

LexCast – the podcast series by MLL NexGen

Smart legal education on the go. The LexCast hosted by MLL NexGen provides legal insights in a short format that allows listeners to educate themselves on and about legal issues wherever they are and whenever they find the time.

Listen to our podcast series – stay tuned.

MLL Legal on Social Media

Follow us on LinkedIn.